Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Disc Medicine Inc., 3 years.
Disc Medicine Inc.
Director
Supernus Pharmaceuticals Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 8, 2024 | Supernus Pharmaceuticals Inc. | Option exercise | +10,787 | $11.46 | $123,619 |
| Nov 8, 2024 | Supernus Pharmaceuticals Inc. | Open-market sale | −10,787 | $36.30 | $391,568 |
| Nov 7, 2024 | Supernus Pharmaceuticals Inc. | Option exercise | +14,213 | $11.46 | $162,881 |
| Nov 7, 2024 | Supernus Pharmaceuticals Inc. | Open-market sale | −14,213 | $36.62 | $520,480 |
| Sep 13, 2024 | Supernus Pharmaceuticals Inc. | Open-market sale | −3,886 | $31.33 | $121,748 |
| Sep 13, 2024 | Supernus Pharmaceuticals Inc. | Option exercise | +10,000 | $11.46 | $114,600 |
| Sep 13, 2024 | Supernus Pharmaceuticals Inc. | Open-market sale | −10,000 | $31.33 | $313,300 |
| Feb 23, 2024 | Supernus Pharmaceuticals Inc. | Grant or award | +3,886 | — | — |
| Feb 22, 2023 | Supernus Pharmaceuticals Inc. | Grant or award | +3,882 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.